Gene · 4751
Papers2,227
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,227
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma. | Sci Adv | 2025 | 40397754 | PubTator, text mining | PubMed |
| Cancer-associated fibroblast-derived fibulin-5 promotes epithelial-mesenchymal transition in diffuse-type gastric cancer via cAMP response element-binding protein pathway, showing poor prognosis. | Exp Mol Med | 2025 | 40369121 | PubTator, text mining | PubMed |
| Bioinformatics analysis across pan-cancer and experimental validation in hepatocellular carcinoma revealed the oncogenic role of SF3B6. | Front Pharmacol | 2025 | 40356980 | PubTator, text mining | PubMed |
| Integrative bioinformatic analysis identifies differentially expressed gene targets as potential biomarkers for anaplastic thyroid cancer. | J Egypt Natl Canc Inst | 2025 | 40350533 | PubTator, text mining | PubMed |
| NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury. | ASPET Discov | 2025 | 40259950 | PubTator, text mining | PubMed |
| NEK2 supports porcine embryonic development by modulating the AKT signaling pathway. | Life Sci | 2025 | 40239862 | PubTator, text mining | PubMed |
| FOXA1 Targets NEK2 to Mediate Cisplatin Resistance in Lung Adenocarcinoma Cells by Activating DNA Damage Repair. | Drug Dev Res | 2025 | 40233258 | PubTator, text mining | PubMed |
| Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma. | Mol Carcinog | 2025 | 40222041 | PubTator, text mining | PubMed |
| NUF2 and NEK2 promote malignant progression of gallbladder cancer by remodeling the extracellular matrix. | Carcinogenesis | 2025 | 40220284 | PubTator, text mining | PubMed |
| KLF15 regulates macrophage polarization patterns in deep vein thrombosis. | Int Immunopharmacol | 2025 | 40215780 | PubTator, text mining | PubMed |
| Application of bioinformatics analysis and molecular docking to study the mechanism of Qingying decoction in treating psoriasis. | Hereditas | 2025 | 40197419 | PubTator, text mining | PubMed |
| Microcystin-LR and its health impacts: Chemistry, transmission routes, mechanisms of toxicity and target organs. | Toxicol Rep | 2025 | 40177604 | PubTator, text mining | PubMed |
| NEK2 promotes cancer cell progression and 5-fluorouracil resistance via the Wnt/β-catenin signaling pathway in colorectal cancer. | Discov Oncol | 2025 | 40153115 | PubTator, text mining | PubMed |
| Exploring the anticancer potential of Jerantinine A from Tabernaemontana coronaria against prostate, breast, and ovarian cancers: a computational approach. | J Complement Integr Med | 2025 | 40147045 | PubTator, text mining | PubMed |
| NEK2 promotes the progression of osteosarcoma through the AKT/p-AKT pathway and interacts with FoxM1. | Med Oncol | 2025 | 40106063 | PubTator, text mining | PubMed |
| Comprehensive analysis of intervention and control studies for the computational identification of dengue biomarker genes. | PLoS Negl Trop Dis | 2025 | 40100920 | PubTator, text mining | PubMed |
| actifpTM: a refined confidence metric of AlphaFold2 predictions involving flexible regions. | Bioinformatics | 2025 | 40080667 | PubTator, text mining | PubMed |
| Targeting NEK Kinases in Gastrointestinal Cancers: Insights into Gene Expression, Function, and Inhibitors. | Int J Mol Sci | 2025 | 40076620 | PubTator, text mining | PubMed |
| Development and validation of a kinase-related gene signature as a novel diagnostic and prognostic model for prostate cancer. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39965532 | PubTator, text mining | PubMed |
| NEK2 Control of Esophageal Squamous Cell Carcinoma Growth Based on Circadian Oscillation. | Cancer Sci | 2025 | 39963019 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4751/papers?page=4